Ontology highlight
ABSTRACT:
SUBMITTER: Tobiasson M
PROVIDER: S-EPMC5438694 | biostudies-literature | 2017 Apr
REPOSITORIES: biostudies-literature
Tobiasson Magnus M Abdulkadir Hani H Lennartsson Andreas A Katayama Shintaro S Marabita Francesco F De Paepe Ayla A Karimi Mohsen M Krjutskov Kaarel K Einarsdottir Elisabet E Grövdal Michael M Jansson Monika M Ben Azenkoud Asmaa A Corddedu Lina L Lehmann Sören S Ekwall Karl K Kere Juha J Hellström-Lindberg Eva E Ungerstedt Johanna J
Oncotarget 20170401 17
Azacitidine (Aza) is first-line treatment for patients with high-risk myelodysplastic syndromes (MDS), although its precise mechanism of action is unknown. We performed the first study to globally evaluate the epigenetic effects of Aza on MDS bone marrow progenitor cells assessing gene expression (RNA seq), DNA methylation (Illumina 450k) and the histone modifications H3K18ac and H3K9me3 (ChIP seq). Aza induced a general increase in gene expression with 924 significantly upregulated genes but th ...[more]